ENVB unveils library of 57+ preclinical compounds targeting mental health disorders

Enveric Biosciences, Inc.

Library spans 7 molecule classes including SNDRIs, NSRIs, MDMA derivatives, psilocin prodrugs, and melatonin agonists.
Compounds are protected by Enveric's IP portfolio and represent potential out-licensing and non-dilutive revenue streams.
Lead candidates EB-003 (non-hallucinogenic neuroplastogen) and EB-002 (psilocin prodrug) remain focus; library adds depth.
Novel MDMA derivatives show varying 5-HT2A binding; some designed to reduce hallucinogenic potential while retaining neuroplasticity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.